Cited by 601Marine Sponges and Natural ProductsMicrobial Natural Products and BiosynthesisIsoquinoline Alkaloid Synthesis

The DOI matches its Crossref record; 74 of the 77 references it cites were found in a registry or an index.

Marine natural products as anticancer drugs

Simmons, T. Luke, Andrianasolo, Eric, McPhail, Kerry, Flatt, Patricia, Gerwick, William H.·2005·Molecular Cancer Therapeutics

DOI 10.1158/1535-7163.333.4.2

Open this paper in CoChat — free account

Abstract

The chemical and biological diversity of the marine environment is immeasurable and therefore is an extraordinary resource for the discovery of new anticancer drugs. Recent technological and methodologic advances in structure elucidation, organic synthesis, and biological assay have resulted in the isolation and clinical evaluation of various novel anticancer agents. These compounds range in structural class from simple linear peptides, such as dolastatin 10, to complex macrocyclic polyethers, such as halichondrin B; equally as diverse are the molecular modes of action by which these molecules impart their biological activity. This review highlights several marine natural products and their synthetic derivatives that are currently undergoing clinical evaluation as anticancer drugs.

Integrity signals

Registry

Crossref · 10.1158/1535-7163.333.4.2

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Environmental genome shotgun sequencing of the sargasso sea
Venter, J. C., Remington, K., Heidelberg, J. F., Halpern, A. L., Rusch, D., Eisen, J. A., Wu, D., Paulsen, I., Nelson, K. E., Nelson, W., et al. (2004) · Science · doi:10.1126/science.1093857 · Cited by 4,376
Natural products as sources of new drugs over the period 1981–2002
Newman, D. J., Cragg, G. M., & Snader, K. M. (2003) · Journal of Natural Products · doi:10.1021/np030096l · Cited by 3,082
Marine Natural Products and Related Compounds in Clinical and Advanced Preclinical Trials
Newman, D. J., & Cragg, G. M. L. (2004) · Journal of Natural Products · doi:10.1021/np040031y · Cited by 758
Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle
Jordan, A. M., Hadfield, J. A., Lawrence, N. J., & McGown, A. T. (1998) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199807)18:4 · Cited by 678
The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10
Pettit, G. R., Kamano, Y., Herald, C. L., Tuinman, A. A., Boettner, F. E., Kizu, H., Schmidt, J. M., Baczynskyj, L., Tomer, K. B., & Bontems, R. J. (1987) · Journal of the American Chemical Society · doi:10.1021/ja00256a070 · Cited by 583
Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata
RINEHART, K. L. J., Holt, T. G., Fregeau, N. L., Stroh, J. G., Keifer, P. A., Sun, F.-R., Li, L. H., & Martin, D. G. (1990) · The Journal of Organic Chemistry · doi:10.1021/jo00302a007 · Cited by 493
In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B.
Towle, M. J., Salvato, K. A., Budrow, J., Wels, B. F., Kuznetsov, G., Aalfs, K. K., Welsh, S., Zheng, W., Seletsky, B. M., Palme, M. H., et al. (2001) · PubMed · Cited by 483
Palytoxin: A New Marine Toxin from a Coelenterate
Moore, R. E., & Scheuer, P. J. (1971) · Science · doi:10.1126/science.172.3982.495 · Cited by 482
Natural products ? a simple model to explain chemical diversity
Firn, R. D., & Jones, C. G. (2003) · Natural Product Reports · doi:10.1039/b208815k · Cited by 467
Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data
Bai, R., Paull, K. D., Herald, C. L., Malspeis, L., Pettit, G. R., & Hamel, E. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98491-7 · Cited by 380
Isolation of Dolastatin 10 from the Marine Cyanobacterium Symploca Species VP642 and Total Stereochemistry and Biological Evaluation of Its Analogue Symplostatin 1
Luesch, H., Moore, R. E., Paul, V. J., Mooberry, S. L., & Corbett, T. H. (2001) · Journal of Natural Products · doi:10.1021/np010049y · Cited by 378
Why Are Secondary Metabolites (Natural Products) Biosynthesized?
Williams, D. H., Stone, M. J., Hauck, P. R., & Rahman, S. K. (1989) · Journal of Natural Products · doi:10.1021/np50066a001 · Cited by 374
Dolastatin 10, a powerful cytostatic peptide derived from a marine animal
Bai, R., Petit, G. R., & Hamel, E. (1990) · Biochemical Pharmacology · doi:10.1016/0006-2952(90)90613-p · Cited by 321
Psammaplins from the Sponge Pseudoceratina purpurea: Inhibition of Both Histone Deacetylase and DNA Methyltransferase
Piña, I. C., Gautschi, J. T., Wang, G.-Y.-S., Sanders, M. L., Schmitz, F. J., France, D. S., Cornell-Kennon, S., Sambucetti, L. C., Remiszewski, S., Perez, L. B., et al. (2003) · The Journal of Organic Chemistry · doi:10.1021/jo034248t · Cited by 314
Norhalichondrin A: an antitumor polyether macrolide from a marine sponge
Uemura, D., Takahashi, K. A., Yamamoto, T., Katayama, C., Tanaka, J., Okumura, Y., & Hiratå, Y. (1985) · Journal of the American Chemical Society · doi:10.1021/ja00302a042 · Cited by 290
Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
Bai, R., Pettit, G. R., & Hamel, E. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44880-0 · Cited by 287
Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinata
Wright, A. E., Forleo, D. A., Gunawardana, G. P., Gunasekera, S. P., Koehn, F. E., & McConnell, O. J. (1990) · The Journal of Organic Chemistry · doi:10.1021/jo00302a006 · Cited by 268
Structures of the didemnins, antiviral and cytotoxic depsipeptides from a Caribbean tunicate
Rinehart, K. L., Gloer, J. B., Cook, J. C., MIZSAK, S. A., & Scahill, T. A. (1981) · Journal of the American Chemical Society · doi:10.1021/ja00397a055 · Cited by 256
Ecteinascidin 743: A Minor Groove Alkylator That Bends DNA toward the Major Groove
Zewail‐Foote, M., & Hurley, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990241l · Cited by 219
Drugs from the Sea
Ruggieri, G. D. (1976) · Science · doi:10.1126/science.9691 · Cited by 210
Cyanobacterial symbiont biosynthesis of chlorinated metabolites fromDysidea herbacea (Porifera)
Unson, M. D., & Faulkner, D. J. (1993) · Cellular and Molecular Life Sciences · doi:10.1007/bf01923420 · Cited by 206
Barbamide, a Chlorinated Metabolite with Molluscicidal Activity from the Caribbean Cyanobacterium Lyngbya majuscula
Orjala, J., & Gerwick, W. H. (1996) · Journal of Natural Products · doi:10.1021/np960085a · Cited by 187
Nitrogen-containing metabolites from marine cyanobacteria
Gerwick, W. H., Tan, L. T., & Sitachitta, N. (2001) · The Alkaloids. Chemistry and biology/The alkaloids. Chemistry and biology · doi:10.1016/s0099-9598(01)57003-0 · Cited by 186
New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials
Jimeno, J. M., Faircloth, G. T., Sousa-Faro, J. M. F., Scheuer, P. J., & RINEHART, K. L. J. (2004) · Marine Drugs · doi:10.3390/md201014 · Cited by 179
Merging the potential of microbial genetics with biological and chemical diversity: an even brighter future for marine natural product drug discovery
Salomon, C. E., Magarvey, N. A., & Sherman, D. H. (2004) · Natural Product Reports · doi:10.1039/b301384g · Cited by 172
Natural products as probes of cell biology: 20 years of didemnin research
Vera, M. D., & Joullié, M. M. (2002) · Medicinal Research Reviews · doi:10.1002/med.10003 · Cited by 153
Isolation and structure of the cytostatic linear depsipeptide dolastatin 15
Pettit, G. R., Kamano, Y., Dufresne, C., Cerny, R. L., Herald, C. L., & Schmidt, J. M. (1989) · The Journal of Organic Chemistry · doi:10.1021/jo00287a003 · Cited by 151
Structure−Activity Relationships of the Didemnins
Sakai, R., Rinehart, K. L., Kishore, V., Kundu, B. K., Faircloth, G. T., Gloer, J. B., Carney, J. R., Namikoshi, M., Sun, F.-R., Hughes, R. G., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960048g · Cited by 150
Progress in the development and acquisition of anticancer agents from marine sources
Amador, M. L., Jimeno, J. M., Paz-Ares, L. G., Cortés-Funes, H., & Hidalgo, M. M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg443 · Cited by 150
Phenolic constituents of
Quiñoá, E., & Crews, P. (1987) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)95478-9 · Cited by 149
Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4
Broggini, M., Marchini, S., Galliera, E., Borsotti, P., Taraboletti, G., Erba, E., Sironi, M., Jimeno, J. M., Faircloth, G. T., Giavazzi, R., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402788 · Cited by 148
Symplostatin 2: A Dolastatin 13 Analogue from the Marine Cyanobacterium Symploca hydnoides
Harrigan, G. G., Luesch, H., Yoshida, W. Y., Moore, R. E., Nagle, D. G., & Paul, V. J. (1999) · Journal of Natural Products · doi:10.1021/np980553b · Cited by 148
Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates
Urdiales, J. L., Morata, P., de Castro, I. N., & Sánchez‐Jiménez, F. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04151-1 · Cited by 142
GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 alpha.
Crews, C. M., Collins, J. L., Lane, W. S., Snapper, M. L., & Schreiber, S. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40692-2 · Cited by 140
Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.
Vaishampayan, U. N., Glodé, M., Du, W., Kraft, A. S., Hudes, G. R., Wright, J. D., & Hussain, M. (2000) · PubMed · Cited by 136
Symplostatin 1: A Dolastatin 10 Analogue from the Marine Cyanobacterium Symploca hydnoides
Harrigan, G. G., Luesch, H., Yoshida, W. Y., Moore, R. E., Nagle, D. G., Paul, V. J., Mooberry, S. L., Corbett, T. H., & Valeriote, F. A. (1998) · Journal of Natural Products · doi:10.1021/np980321c · Cited by 133
Brominated tyrosine metabolites from an unidentified sponge
Arabshahi, L., & Schmitz, F. J. (1987) · The Journal of Organic Chemistry · doi:10.1021/jo00392a016 · Cited by 130
A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction
Ajani, J. A., Komaki, R. U., Putnam, J. B., Walsh, G. L., Nesbitt, J., Pisters, P. W. T., Lynch, P. M., Vaporciyan, A. A., Smythe, R. W., Lahoti, S., et al. (2001) · Cancer · doi:10.1002/1097-0142(20010715)92:2 · Cited by 117
Synthesis and Antitumor Activity of Novel Dolastatin 10 Analogs.
MIYAZAKI, K., Kobayashi, M., Natsume, T., Gondo, M., Mikami, T., SAKAKIBARA, K., & Tsukagoshi, S. (1995) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.43.1706 · Cited by 111
Cellular origin of chlorinated diketopiperazines in the dictyoceratid sponge Dysidea herbacea (Keller)
Flowers, A. E., Garson, M. J., Webb, R. I., Dumdei, E. J., & Charan, R. D. (1998) · Cell and Tissue Research · doi:10.1007/s004410051089 · Cited by 109
Approaches to identify, clone, and express symbiont bioactive metabolite genes
Hildebrand, M., Waggoner, L. E., Lim, G. E., Sharp, K. H., Ridley, C. P., & Haygood, M. G. (2004) · Natural Product Reports · doi:10.1039/b302336m · Cited by 106
Antitumor Activity of TZT‐1027, a Novel Doiastatin 10 Derivative
Kobayashi, M., Natsume, T., Tamaoki, S., Watanabe, J., Asano, H., Mikami, T., Miyasaka, K., Miyazaki, K., Gondo, M., SAKAKIBARA, K., et al. (1997) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1997.tb00383.x · Cited by 103
Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
Pitot, H. C., McElroy, E., Reid, J. M., Windebank, A. J., Sloan, J. A., Erlichman, C., Bagniewski, P. G., Walker, D. L., Rubin, J., Goldberg, R. M., et al. (1999) · PubMed · Cited by 101
The Discovery of NVP-LAQ824: From Concept to Clinic
Remiszewski, S. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456675 · Cited by 88
Yondelis® (trabectedin, ET-743): the development of an anticancer agent of marine origin
van Kesteren, C., de Vooght, M. M. M., Lázaro, L. L., Mathôt, R. A. A., Schellens, J. H. M., Jimeno, J. M., & Beijnen, J. H. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200308000-00001 · Cited by 88
Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro
Shim, J. S., Lee, H., Shin, J., & Kwon, H. J. (2003) · Cancer Letters · doi:10.1016/j.canlet.2003.08.036 · Cited by 78
Symbiotic Bacteria in Sponges: Sources of Bioactive Substances
Faulkner, D. J., Harper, M. K., Haygood, M. G., Salomon, C. E., & Schmidt, E. W. (2000) · KARGER eBooks · doi:10.1159/000062486 · Cited by 75
Biochemical and cellular effects of didemnins A and B.
Crampton, S. L., Adams, E. G., Kuentzel, S. L., Li, L. H., Badiner, G. J., & Bhuyan, B. K. (1984) · PubMed · Cited by 74
Synthetic studies on the marine natural product halichondrins
Choi, H.-W., Demeke, D., Kang, F., Kishi, Y., Nakajima, K., Nowak, P., Wan, Z., & Xie, C. (2003) · Pure and Applied Chemistry · doi:10.1351/pac200375010001 · Cited by 72
Pharmaceutical development of anticancer agents derived from marine sources
Nuijen, B., Bouma, M., Manada, C., Jimeno, J. M., Schellens, J. H. M., Bult, A., & Beijnen, J. H. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200011000-00003 · Cited by 71
A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study
Hoffman, M. A., Blessing, J. A., & Lentz, S. S. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00007-6 · Cited by 69
Two bromotyrosine-cysteine derived metabolites from a sponge
Rodrı́guez, A. D., Akee, R. K., & Scheuer, P. J. (1987) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)96677-2 · Cited by 67
Genetic Evidence Supports Secondary Metabolic Diversity in Prochloron spp., the Cyanobacterial Symbiont of a Tropical Ascidian
Schmidt, E. W., Sudek, S., & Haygood, M. G. (2004) · Journal of Natural Products · doi:10.1021/np049948n · Cited by 65
Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells.
Kim, D., Lee, I. S., Jung, J. Y., Lee, C. O., & Choi, S. U. (1999) · PubMed · Cited by 64
Compounds produced from potential tunicate-blue-green algal symbiosis: A review
Sings, H. L., & RINEHART, K. L. J. (1996) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/bf01574769 · Cited by 62
LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis.
de Arruda, M., Cocchiaro, C., Nelson, C. M., Grinnell, C. M., Janssen, B., Haupt, A., & Barlozzari, T. (1995) · PubMed · Cited by 62
Structure–activity relationships of Halichondrin B analogues: modifications at C.30–C.38
Wang, Y., Habgood, G. J., Christ, W. J., Kishi, Y., Littlefield, B. A., & Yu, M. J. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00150-5 · Cited by 61
Localization Studies of Bioactive Cyclic Peptides in the Ascidian Lissoclinum patella
Salomon, C. E., & Faulkner, D. J. (2002) · Journal of Natural Products · doi:10.1021/np010556f · Cited by 58
Venom of the lionfish Pterois volitans
Saunders, P. R., & Taylor, P. B. (1959) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1959.197.2.437 · Cited by 56
Total synthesis of halichondrins: Enantioselective construction of a homochiral pentacyclic C1-C15 intermediate from d-ribose
Cooper, A. J., & Salomon, R. G. (1990) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)97476-8 · Cited by 54
Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer
Kerbrat, P., Dieras, V. C., Pavlidis, N. A., Ravaud, A., Wanders, J., & Fumoleau, P. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00531-2 · Cited by 53
Effect of Aplidin in acute lymphoblastic leukaemia cells
Erba, E., Serafini, M., Gaipa, G., Tognon, G., Marchini, S., Celli, N., Rotilio, D., Broggini, M., Jimeno, J. M., Faircloth, G. T., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601130 · Cited by 53
Antitumor activity of TZT‐1027 (Soblidotin) against vascular endothelial growth factor‐secreting human lung cancer in vivo
Natsume, T., Watanabe, J., Koh, Y., Fujio, N., Ohe, Y., Horiuchi, T., Saijo, N., Nishio, K., & Kobayashi, M. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01526.x · Cited by 49
Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel–Dreyer chromatography
Cruz‐Monserrate, Z., Mullaney, J. T., Harran, P. G., Pettit, G. R., & Hamel, E. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03776.x · Cited by 49
Peptides isolated from the venom of Conus geographus block neuromuscular transmission
McManus, O. B., Musick, J. R., & González, C. (1981) · Neuroscience Letters · doi:10.1016/0304-3940(81)90101-4 · Cited by 45
A Phase II Study of the Dolastatin 15 Analogue LU 103793 in the Treatment of Advanced Non–Small-Cell Lung Cancer
Marks, R. S., Graham, D. L., Sloan, J. A., Hillman, S. H., Fishkoff, S., Krook, J. E., Okuno, S. H., Mailliard, J. A., Fitch, T. R., & Addo, F. (2003) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000020962.25210.6f · Cited by 39
Activity of the dolastatin analogue, LU103793, in malignant melanoma
Smyth, J., Bonneterre, M.-E., Schellens, J. H. M., Calvert, H., Greim, G., Wanders, J., & Hanauske, A. (2001) · Annals of Oncology · doi:10.1023/a:1011194910571 · Cited by 36
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.
Villalona-Calero, M. A., Baker, S. D., Hammond, L. A., Aylesworth, C., Eckhardt, S. G., Kraynak, M. A., Fram, R. J., Fischkoff, S. A., Velagapudi, R. B., Toppmeyer, D., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2770 · Cited by 32
Rapamycin inhibits didemnin B‐induced apoptosis in human HL‐60 cells: Evidence for the possible involvement of FK506‐binding protein 25
Johnson, K. L., & Lawen, A. (1999) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.1999.00821.x · Cited by 30
Phase II study of synthadotin (SYN-D; ILX651) administered daily for 5 consecutive days once every 3 weeks (qdx5q3w) in patients (Pts) with inoperable locally advanced or metastatic melanoma
Ebbinghaus, S., Hersh, E., Cunningham, C. C., O'Day, S. J., McDermott, D. F., Stephenson, J. R., Richards, D., Eckardt, J. R., Haider, O., & Hammond, L. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.7530 · Cited by 23
A quantitative evaluation of the effects of inhibitors of tubulin assembly on polymerization induced by discodermolide, epothilone B, and paclitaxel
Dabydeen, D. A., Florence, G. J., Paterson, I., & Hamel, E. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0755-0 · Cited by 21
National Cooperative Drug Discovery Groups (NCDDGs): A Successful Model for Public Private Partnerships in Cancer Drug Discovery
Hallock, Y. F., & Cragg, G. M. L. (2003) · Pharmaceutical Biology · doi:10.1080/13880200390517779 · Cited by 19
A phase II study of trabectedin (ET-743) as a second line therapy in patients with persistent or recurrent endometrial carcinoma
McMeekin, D. S., Manikas, G., Crispens, M. A., Orza, A. M., Braly, P. S., Doering, D. L., Trifan, O. C., Michiels, B., & Markman, M. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.5086 · Cited by 6
A phase II study of weekly trabectedin (ET-743) in second/third line ovarian carcinoma
Krasner, C. N., McMeekin, S., Chan, S. Y. T., Braly, P. S., Kaye, S. B., Provencher, D. M., Klecz, J., Michiels, B., de Velde, H. V., & Gore, M. E. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.5045 · Cited by 3

Research works printed but not linked: 3

Armand JP, Ady-Vago N, Faivre S, et al. Phase I and Pharmacokinetic Study of Aplidine (APL) given as a 24-hour continuous infusion every other week (q2w) in patients (pts) with solid tumor (ST) and lymphoma (NHL). Proceedings of the 2001 American Society of Clinical Oncology Annual Meeting. Abstr #47. In 2001.
Dileo P, Casali PG, Bacci G, et al. Phase II evaluation of 3-hr infusion ET-743 in patients with recurrent sarcomas. Proceedings of the 2002 ASCO Annual Meeting. Abstr #1628. In 2002.
Kimura T, Synold T, Mahaffey CM, et al. E7389, a novel antimicrotubule agent with potent p53-independent induction of p27, Bcl2 phosphorylation and cytotoxicity in non-small cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology. Abstr. # 2804. In 2003. p. 697.

Sorted by citations

Sponge-Associated Microorganisms: Evolution, Ecology, and Biotechnological Potential
Taylor, M. W., Radax, R., Steger, D., & Wagner, M. (2007) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00040-06 · Cited by 1,493
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Natural products as leads to anticancer drugs
Gordaliza, M. (2007) · Clinical & Translational Oncology · doi:10.1007/s12094-007-0138-9 · Cited by 707
Patellamide A and C biosynthesis by a microcin-like pathway in Prochloron didemni , the cyanobacterial symbiont of Lissoclinum patella
Schmidt, E. W., Nelson, J. T., Rasko, D. A., Sudek, S., Eisen, J. A., Haygood, M. G., & Ravel, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501424102 · Cited by 567
Marine Natural Products: A Source of Novel Anticancer Drugs
Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555

See all 601

Authors: Simmons, T. L., Andrianasolo, E., McPhail, K., Flatt, P., & Gerwick, W. H.
Affiliations: Oregon State University (US)
ORCID: McPhail, Kerry
Gerwick, William H.
Venue: Molecular Cancer Therapeutics
Publisher: American Association for Cancer Research (AACR)
Published: 2005-02-01
Volume: 4
Issue: 2
Pages: 333-342
ISSN: 1535-7163 (ISSN-L)
1538-8514
DOI: 10.1158/1535-7163.333.4.2
OpenAlex: W2169637929
Cited by: 597
References: 77
Citations by year: 2026: 10 · 2025: 6 · 2024: 13 · 2023: 21 · 2022: 15 · 2021: 31 · 2020: 36 · 2019: 37 · 2018: 25 · 2017: 32 · 2016: 32 · 2015: 40 · 2014: 40 · 2013: 40 · 2012: 42
FWCI: 21.36
Type: journal article
Language: en
Open access: closed
Locations: Molecular Cancer Therapeutics (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Marine Sponges and Natural Products
Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
Physical Sciences › Chemistry › Organic Chemistry › Isoquinoline Alkaloid Synthesis
Keywords: marine natural products, anticancer agents, dolastatin 10, halichondrin B, macrocyclic polyethers, marine peptides, structure elucidation, organic synthesis, clinical evaluation, mechanism of action
MeSH terms: Trabectedin, Polyether Polyketides, Animals, Antineoplastic Agents, Biological Products, Dioxoles, Ethers, Cyclic, Humans, Isoquinolines, Oceans and Seas, Tyrosine, Macrolides, Tetrahydroisoquinolines, Depsipeptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Marine natural products as anticancer drugs

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks